Survival Factors in Nasopharyngeal Carcinoma with Lung Metastasis
Author Information
Author(s): Cao Xun, He Li-Ru, Xie Fang-Yun, Chen You-Fang, Wen Zhe-Sheng
Primary Institution: Sun Yat-Sen University Cancer Center
Hypothesis
Does combined modality treatment benefit nasopharyngeal carcinoma patients with lung metastasis alone?
Conclusion
Combined therapy improves survival for nasopharyngeal carcinoma patients with lung metastasis who have a disease-free interval greater than one year.
Supporting Evidence
- The 3-year overall survival rate was 67.8% for the cohort.
- Patients treated with combined therapy had a median overall survival of 73.7 months.
- Age, disease-free interval, and treatment modality were significant prognostic factors.
Takeaway
This study found that younger patients and those who had a longer time without cancer before lung metastasis did better when treated with a combination of therapies.
Methodology
Retrospective review of 246 patients with nasopharyngeal carcinoma and lung metastasis, analyzing survival data and treatment outcomes.
Potential Biases
Potential selection bias due to the retrospective nature and single-center design.
Limitations
The study is retrospective and based on a single institution's data, which may limit generalizability.
Participant Demographics
{"age":{"≤ 45":130,"> 45":116},"gender":{"male":196,"female":50}}
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website